Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
Haematologica|December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialMeletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
Journal of Geriatric Oncology|March 2, 2021
Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 studyVincent Thibaud, Laurence Denève, Stéphanie Dubruille, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantationStef Meers, Katrien Lagrou, Koen Theunissen, et al.
Leukemia & Lymphoma|April 26, 2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myelomaPaula Rodriguez-Otero, Dieter Ayers, Shannon Cope, et al.
JACC. Cardiovascular Imaging|February 18, 2019
Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac AmyloidosisAniela Petrescu, Pedro Santos, Marta Orlowska, et al.
Journal of Cardiothoracic and Vascular Anesthesia|February 6, 2008
Aprotinin reduces cardiac troponin I release and inhibits apoptosis of polymorphonuclear cells during off-pump coronary artery bypass surgeryChristophe Bert, Frederik De Buck, Paul Sergeant, et al.
Genes, Chromosomes & Cancer|April 8, 2020
Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myelomaLieselot Buedts, Sanne Smits, Geneviève Ameye, et al.
The Lancet. Oncology|October 12, 2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesMichel Delforge, Joan Bladé, Meletios A Dimopoulos, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
EANM guidelines on the use of [<sup>18</sup>F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disordersCristina Nanni, Christophe M Deroose, Sona Balogova, et al.
Haematologica|November 22, 2011
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia GroupFrédéric Baron, Stefan Suciu, Sergio Amadori, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Haematologica|December 18, 2012
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialMeletios A Dimopoulos, Michel Delforge, Roman Hájek, et al.
Journal of Geriatric Oncology|March 2, 2021
Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 studyVincent Thibaud, Laurence Denève, Stéphanie Dubruille, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantationStef Meers, Katrien Lagrou, Koen Theunissen, et al.
Leukemia & Lymphoma|April 26, 2021
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myelomaPaula Rodriguez-Otero, Dieter Ayers, Shannon Cope, et al.
JACC. Cardiovascular Imaging|February 18, 2019
Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac AmyloidosisAniela Petrescu, Pedro Santos, Marta Orlowska, et al.
Journal of Cardiothoracic and Vascular Anesthesia|February 6, 2008
Aprotinin reduces cardiac troponin I release and inhibits apoptosis of polymorphonuclear cells during off-pump coronary artery bypass surgeryChristophe Bert, Frederik De Buck, Paul Sergeant, et al.
Genes, Chromosomes & Cancer|April 8, 2020
Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myelomaLieselot Buedts, Sanne Smits, Geneviève Ameye, et al.
The Lancet. Oncology|October 12, 2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesMichel Delforge, Joan Bladé, Meletios A Dimopoulos, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
EANM guidelines on the use of [<sup>18</sup>F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disordersCristina Nanni, Christophe M Deroose, Sona Balogova, et al.
Haematologica|November 22, 2011
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia GroupFrédéric Baron, Stefan Suciu, Sergio Amadori, et al.
Pageof 19